Phase III randomized sequential open-label study to evaluate the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX+ bevacizumab followed by FOLFIRI + panitumumab (Sequence 2) in untreated patients with wild-type RAS metastatic, primary left (L)-sided, unresectable colorectal cancer (CRC): The CR-SEQUENCE.

Ramon Salazar,Alfredo Carrato,T. Garcia,Javier Gallego Plazas,Auxiliadora Gómez-España,Cristina Grávalos Castro,M. Pilar Escudero,Maria Jose Safont,Antonieta Salud-Salvia,Carles Pericay,Begoña Graña Suárez,David Marrupe,Rosario Vidal,Ferran Losa,Teresa Rodríguez,José Luis Manzano Mozo,Josep Tabernero,Helder Mansinho,Clara Montagut,Enrique Aranda

Phase III randomized sequential open-label study to evaluate the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX+ bevacizumab followed by FOLFIRI + panitumumab (Sequence 2) in untreated patients with wild-type RAS metastatic, primary left (L)-sided, unresectable colorectal cancer (CRC): The CR-SEQUENCE.

2019

TPS3618Background: Both anti-EGFR and anti-VEGF therapies have shown clinical benefit when they are added in first and second-line in L-sided CRC. The conflicting results in anti-VEGF vs. anti-EGFR...

Keywords:

Wild type
Bevacizumab
FOLFIRI
Colorectal cancer
Panitumumab
FOLFOX
Oncology
Pathology
Medicine
Internal medicine
open label study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations